An interventional study of prednisone,methylprednisone and cyclophosphamide and Rituximab in Mild Cognitive Impairment and Idiopathic Membranous Nephropathy, sponsored by Beijing Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-07.
Sponsored by Beijing Friendship Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 310 studies in Cognitive Dysfunction with a site in China — 144 open to participants now, 156 under way, 8 of them phase 3. Cognitive Dysfunction · China.
Among the 310 studies in Cognitive Dysfunction with a site in China, this one is the 187th largest by planned enrollment of the 191 interventional ones that give a count, is one of 31 that started in 2023, is one of 139 with no phase, reaches primary completion later than 33 of the 155 other live ones, and was the 161st registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →144 of the 310 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:
Central South University · Sites in China
Ages 18–35
Shanghai University of Sport · Sites in China
Ages 60–80
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Sites in China
Ages 35–80
Beijing Tiantan Hospital · Sites in China
Ages 12–70
Shanghai University of Sport · Sites in China
Ages 65+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
310 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 17 · Phase 4 15
First in 2000; this study’s year is marked. 31 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 110 across the 191 interventional studies, 300 across the 119 observational. Of the 90 that completed or were terminated, 3 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 310 have an industry lead sponsor. The 10 most frequent:
Beijing Friendship Hospital is the lead sponsor of 217 studies on the registry; 94 are open to participants now.
Beijing Friendship Hospital has 4 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
34 of the studies in Cognitive Dysfunction with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07603102Nanjing Mingzhou Rehabilitation HospitalMindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment | 2026-11 |
| NCT06417086ZhanYJClinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers | 2026-11-30 |
| NCT07760415Xiangya Hospital of Central South UniversityEEG Changes and Cognitive Profiles in Sepsis Patients With Different Inflammatory Phenotypes | 2026-12-12 |
| NCT03810794Jian Pei,MDClinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease | 2026-12-30 |
Add all 34 to your calendar (.ics) → With an account.
Among the 310 studies in Cognitive Dysfunction with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study intends to apply prospective, open, single-center, randomized controlled study to evaluate the cognitive status of patients with Idiopathic membranous nephropathy and the influence of different treatment schemes on the cognitive status of patients with Idiopathic membranous nephropathy, and explore the possible pathophysiological mechanism by using brain magnetic resonance imaging technology.
Proteinuia is an independent risk factor for cognitive dysfunction and dementia. There is no relevant research on whether patients with Idiopathic membranous nephropathy with normal renal function are complicated with cognitive impairment. In the process of clinical diagnosis and treatment, it was observed that the cognitive function of patients with Idiopathic membranous nephropathy decreased significantly after treatment compared with that before treatment. However, there is no clinical study to confirm this phenomenon at present, and the causes of cognitive function damage are not clear. This study intends to apply prospective, open, single-center, randomized controlled study to evaluate the cognitive status of patients with Idiopathic membranous nephropathy and the influence of different treatment schemes on the cognitive status of patients with Idiopathic membranous nephropathy, and explore the possible pathophysiological mechanism by using brain magnetic resonance imaging technology, so as to fill the research gap of clinical cognitive status of Idiopathic membranous nephropathy and provide theoretical basis for better clinical treatment scheme selection and prevention of cognitive impairment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with idiopathic membranous nephropathy were treated with Ponticelli protocol,that is alternating prednisone or methylprednisone -cyclophosphamide every other month
Drug: prednisone,methylprednisone and cyclophosphamide
Patients with idiopathic membranous nephropathy were treated with Rituximab.The specific dosage of rituximab depends on the guidance of peripheral blood B cells.
Drug: Rituximab
Drug pages: PrednisoneStudies of PrednisonePrednisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · 6α-methylprednisoneStudies of 6α-methylprednisone6α-methylprednisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
In the first month, methylprednisolone 500mg/d was given intravenously for 3 days, and then prednisone 0.5 mg/(kg d) \* for 27 days. Oral cyclophosphamide 2.0 mg/(kg d) \* 30 days in the second month. After that, the first month and the second month plan were repeated twice.
The dosage of rituximab depends on peripheral blood B cells. After the treatment of rituximab, the peripheral blood B cells were in a clear state and then stopped. After monitoring the recovery of B cells, additional doses were given.
The cognitive function of the two groups was evaluated and analyzed by the Chinese version of Montreal Cognitive Assessment Scale (MoCA)
The two groups of patients were given a quiet environment and completed the test within 10 minutes. The cognitive function of the two groups was evaluated and analyzed by the Chinese version of Montreal Cognitive Assessment Scale (MoCA). The possible score was between 0 and 30. The higher the score, the better the cognitive state. We defined cognitive impairment as a total score of less than 26 for participants with high school education or below and less than 27 for participants with high school education or above, because the average score of MOCA varies according to the level of education
Time frame: enrollment, half a year after treatment and one year after treatment.
Brain magnetic resonance high-resolution structural imaging was performed to observe the changes of brain structure
All participants were examined with 3.0T MRI scanner (GE Healthcare, discovery mr750w, Milwaukee, WI), using quantitative techniques such as high-resolution structural magnetic resonance, resting state functional magnetic resonance and arteriovenous spin labeling imaging (ASL).
Time frame: enrollment, half a year after treatment and one year after treatment.
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Sep 2025, 23 months after the start.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 23 months is below that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Prednisone · 6α-methylprednisone · Cyclophosphamide · Rituximab